Claritin-D® provides significant relief for patients with allergic rhinitis with nasal symptoms7
Claritin-D® starts to work in as little as 30 minutes8
- Onset of action for allergies with nasal congestion in as little as 30 minutes8
- Relief starts in 30 minutes, while an INS can take up to 12 hours for relief and can take between 3 to 14 days to reach maximum efficacy levels8-14,§
- In a clinical study, Claritin-D® provided significantly greater relief of nasal congestion and runny nose vs placebo7
*Physician-evaluated scores.
†P≤0.02.
‡P ≤0.05 vs placebo.
§INS onset based on various dosing instructions; time to maximum efficacy depends on the INS brand.
Adapted from Kaiser et al, 1998.
A double-blind, placebo-controlled, multicenter study involving 469 patients with mild-to-moderate SAR symptoms.
INS=intranasal steroid; SAR=seasonal allergic rhinitis.
In a clinical trial, Claritin-D® 12-hour provided 30% more nasal airflow at hour 115,*
*Based on max air intake through the nose after the first dose.
†P<0.05 vs corresponding placebo.
Treatment phase baseline PNIF is from the highest of 3 measured values prior to study treatment. P values and estimates at each timepoint are from a mixed effects model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.
Note: The maximum PNIF value from each timepoint is summarized.
PNIF=peak nasal inspiratory flow.
Claritin-D® 12-hour provided an improvement of nasal airflow at least 2 times more than Flonase at hour 115,*
*Based on max air intake through the nose after the first dose.
†P<0.05 vs fluticasone nasal spray.
Treatment phase baseline PNIF is from the highest of 3 measured values prior to study treatment. P values and estimates at each timepoint are from a mixed effects model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.
Note: The maximum PNIF value from each timepoint is summarized.
Claritin-D® 12-hour:
Better outcomes at 240 minutes vs Flonase or placebo for entire study duration15
- Average percent change in PNIF was significantly greater with Claritin-D® vs Flonase nasal spray or placebo throughout the study period
*P<0.05 vs fluticasone nasal spray.
†P<0.05 vs corresponding placebo.
Treatment phase baseline PNIF is from the highest of 3 measured values prior to study treatment. P values and estimates at each timepoint are from a mixed effects model with sequence, period, and treatment as fixed effects and subject within sequence as a random effect.
Note: The maximum PNIF value from each timepoint is summarized.
PNIF=peak nasal inspiratory flow.
CLARITIN-D® IS INDICATED TO RELIEVE MORE TYPES OF ALLERGY SYMPTOMS THAN FLONASE BASED ON APPROVED LABEL INDICATIONS
CLARITIN-D® PATIENT TYPES
- Patients with allergic rhinitis with nasal congestion
- Patients concerned about drowsiness
- Patients seeking once-daily treatment
- Patients who want nasal congestion relief
- Patients already on Claritin® who want to add a decongestant
- Patients who appreciate an oral tablet vs a spray
CLARITIN® SAMPLES & COUPONS
Claritin® offers allergy relief for kids and adults in a variety of forms and flavors.
Help your patients tackle their tough allergy symptoms with samples and coupons for Claritin® products.
References: 1. Meltzer EO, Farrar JR, Sennett C. Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients. J Allergy Clin Immunol Pract. 2017;5(3):77-789. doi:10.1016/j.jaip.2016.10.010 2. Blaiss MS, Meltzer EO, Derebery MJ, Boyle JM. Patient and healthcare-provider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(Suppl 1):S4-S10. doi:10.2500/aap.2007.28.2991 3. Meltzer EO, Blaiss MS, Naclerio RM, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. Allergy Asthma Proc. 2012;33(Suppl 1):S113-S141. doi:10.2500/aap.2012.33.3603 4. Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012;8(1):1-11. doi:10.1186/1710-1492-87 5. Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin lmmunol. 2009;124(3 Suppl):S43-S70. doi:10.1016/j.jaci.2009.05.013 6. Allergy & Asthma Network. Understanding allergies. 2020. 7. Kaiser HB, Banov CH, Berkowitz RR, et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. Am J Ther. 1998;5(4):245-251. 8. Georgitis JW, Meltzer EO, Kaliner M, Weiler J, Berkowitz R. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. Ann Allergy Asthma lmmunol. 2000;84(4):451-459. 9. Flonase® website. Accessed December 8, 2021. https://www.flonase.com/faqs/ 10. Flonase®. Prescribing Information. GlaxoSmithKline; 2019. 11. Flonase® website. Accessed December 8, 2021. https://www.gskhealthpartner.com/en-us/respiratory-health/brands/flonase-products/flonase/dosing-administration-flonase-allergy-relief/ 12. Nasacort® website. Accessed December 8, 2021. https://www.nasacort.com/hcp/faqs.html 13. Nasacort®. Prescribing Information. Sanofi-Aventis; 2008. 14. Rhinocort® website. Accessed December 8, 2021. https://www.rhinocortprofessional.com/clinical-data/onset 15. Ng CC, Romaikin D, Steacy LM, et al. Comparative nasal airflow with loratadine-pseudoephedrine and fluticasone nasal spray for allergic rhinitis. Ann Allergy Asthma Immunol. 2021;S1081-1206(21)00348-3. doi:10.1016/j.anai.2021.05.001 16. Claritin-D® 12 Hour Drug Facts. NDA019670. 17. Flonase® Drug Facts. NDA205434.
